Clinical trials: Drug-induced Liver Injury
Drug-Induced Acute Liver Injury
The Multi-Center, Randomized, Double-blind, Positive Controlled Clinical Trial of Bicyclol in the Treatment of Acute DILI
The study adopted the design of multi-center, randomized, double-blind, positive control drug, superiority test, using the double-blind double-simulating skills.
- Trial name
- NCT05063500
- Testing
- bicyclol, 25mg/ tablet, polyene phosphatidylcholine capsules, 228mg/ particle.
- Where
- 2 sites in China
- Volunteers
- 360 people
- Sponsor
- Drug Induced Liver Disease Study Group
Acetaminophen, Drug-Induced Liver Injury
Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study
Acetaminophen (APAP) is the most commonly used NSAIDS in clinic, and it is also a common cause of drug-induced liver injury (DILI).
- Conditions
- Acetaminophen, Drug-Induced Liver Injury, Pharmacogenetics, China
- Trial name
- PAIN (NCT04964310)
- Testing
- genetic polymorphism
- Where
- China
- Volunteers
- 339 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Acetaminophen, Drug Overdose
Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose
This study is a randomized, placebo-controlled double-blinded clinical trial of patients presenting with acetaminophen poisoning who are at increased risk of developing liver injury.
- Conditions
- Acetaminophen, Drug Overdose, Acetaminophen Overdose, Acetaminophen Poisoning
- Trial name
- NCT05517668
- Testing
- Intravenous infusion of N-acetylcysteine, Intravenous infusion of Fomepizole (4-MP)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Richard Dart, MD, PhD
Drug-induced Liver Injury,Chronic
Efficacy and Safety of Glucocorticosteroid Treatment in the Patients With Chronic Recurrent DILI
This study is to observe the efficacy and safety of glucocorticosteroid treatment in the patients with chronic recurrent drug-induced liver injury (DILI).
- Trial name
- NCT02651350
- Testing
- Methylprednisolone, Standard Treatment
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Beijing 302 Hospital
Chronic Pain, Chronic Pain Syndrome
Outcomes Mandate National Integration With Cannabis as Medicine
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
- Conditions
- Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma
- Trial name
- OMNI-Can (NCT03944447)
- Testing
- Cannabis, Medical, RYAH-Medtech Inhaler
- Where
- 17 sites in United States
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- OMNI Medical Services, LLC
Tuberculosis Infection
Analysis of Liver Injury Risk Factors in a Multiethnic Population Treated With Antituberculosis Drugs
Tuberculosis (TB) is the world's second leading cause of death from a single infectious agent after COVID-19. In 2022, TB was estimated to have affected 10.6 million people, of whom 1.3 million died because of it, despite the…
- Trial name
- TUBILI (NCT06539455)
- Testing
- standard anti-TB treatment
- Where
- Italy
- Volunteers
- 127 people
- Sponsor
- Stefania Cheli
Drug-induced Liver Injury, Gut Microbiota
Alterations of Gut Microbiota and Serum Biochemical Markers in DILI Patients
Drug-induced liver injury is a leading cause of acute liver failure worldwide and one of the least understood areas in hepatology research.
- Conditions
- Drug-induced Liver Injury, Gut Microbiota, Biochemical Markers
- Trial name
- NCT05465642
- Testing
- Collect stool and blood samples from patients
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Drug Induced Liver Injury, Tuberculosis (TB)
Comparison of the Outcome of Treatment With Silymarin or N-Aceylcysteine in Patients Taking Anti-Tuberculous Drugs for Tuberculosis at a Tertiary Care Hospital , Karachi
OBJECTIVE : To compare the outcome of treatment with silymarin or N-acetyl cysteine in patients taking anti-tuberculous drugs for tuberculosis at Tertiary Care Hospital, Karachi.
- Trial name
- NCT07058090
- Testing
- Silymarin 420 mg, N Acetyl Cysteine, Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
- Volunteers
- 410 people
- Sponsor
- Liaquat National Hospital & Medical College
Liver Toxicity, Chemically-Induced
Livertoxcicity in Acute Leukemia Patients During Chemotherapy Treatment
Detection of hepatotoxcicity in acute leukemia and study the outcome of acute leukemia patients that suffer from hepatic toxiciyt
- Trial name
- NCT06383325
- Testing
- Chemotherapy
- Volunteers
- 70 people
- Sponsor
- Assiut University
Drug-induced Disorder of Liver, Adverse Reaction to Drug
Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity
Drug metabolism in the liver is subject to large fluctuations (differences between women and men, people of different ethnic backgrounds, children and adults).
- Trial name
- NCT02353455
- Testing
- Blood sampling
- Where
- 5 sites in Australia, Germany and 3 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Andreas Benesic, MD
Brain Tumor, Central Nervous System Tumor
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
RATIONALE: Sodium thiosulfate may reduce or prevent hearing loss in young patients receiving cisplatin for cancer. It is not yet known whether sodium thiosulfate is more effective than no additional treatment in preventing…
- Conditions
- Brain Tumor, Central Nervous System Tumor, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
- Trial name
- NCT00716976
- Testing
- sodium thiosulfate, examination
- Where
- 76 sites in United States, Australia and 1 more
- Volunteers
- 131 people
- Sponsor
- Children's Oncology Group
Liver Injury, Liver Injury, Drug-Induced
A Retrospective Study in Patients With Liver Injury After the Use of Novel Antineoplastic Agents
This is an open-enrollment, retrospective, observational study without interventions. Its primary objective is to understand 1) incidence of liver injury among all the hospitalized patient from participating centers after the…
- Trial name
- NCT06670391
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Drug Induced Liver Disease Study Group
Drug-induced Liver Injury
Establishment of Drug-induced Liver Injury Databases and Application of Circulating microRNA(miRNA)
The purpose of the study is to establish drug-induced liver injury databases in China, make criteria for Chinese drug-induced liver injury patients and evaluate the application of certain circulating miRNA in diagnosis or…
- Trial name
- NCT02061826
- Where
- China
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Beijing Ditan Hospital
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Drug-Induced Liver Injury
Surveillance for Early Liver Injuries Caused by Zhuanggu Guanjie Pill
This is a prospective registry study to surveil early liver injuries caused by Zhuanggu Guanjie Pill (ZGGJ Pill) through a non-intervention observational way.
- Trial name
- NCT03060252
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Beijing 302 Hospital
Drug-induced Liver Injury
A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P）
This is a multi-center, prospective, non-interventional cohort study . Its primary objectives are: 1. assess DILI patients' clinical characteristics, disease progression and influencing factors in clinical practice; 2.
- Trial name
- DILI-P (NCT02961413)
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Drug Induced Liver Disease Study Group
Drug-induced Liver Injury
Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo
In this clinical study silymarin will be administered in different dosages and compared to placebo in order to address if the liver protecting features of silymarin, measured by changes of liver enzyme concentration, can be…
- Trial name
- SILVER (NCT05144217)
- Testing
- 2x 140 mg per day, 3x 280 mg per day, 1x 1120 mg
- Where
- 2 sites in Germany
- Volunteers
- 19 people
- Sponsor
- Prof. Dr. Frank Behrens
Drug Induced Liver Injury
Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia
Drug-induced liver injury (DILI) can lead to potentially fatal complications, such as acute liver failure and even death. In clinical practice, glucocorticoids have been considered in some cases of DILI, especially patients with…
- Trial name
- NCT06922669
- Testing
- Methylprednisolone, Magnesium isoglycyrrhizinate, Glutathione
- Where
- China
- Volunteers
- 232 people
- Sponsor
- General Hospital of Shenyang Military Region
Hepatitis, Drug-Induced
Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis
This clinical trial is to clarify and investigate the patterns of immune-related hepatitis and the optimal treatment choice for patients who are steroid-dependent.
- Trial name
- I-HEP (NCT04810156)
- Testing
- Mycophenolate Mofetil, Solu-Medrol, Ursodeoxycholic acid
- Where
- 5 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Inge Marie Svane
Drug-Induced Liver Injury
Surveillance for Early Liver Injuries Caused by Xianlin Gubao Pill.
This is a prospective registry study to surveil early liver injuries caused by Xianlin Gubao Pill (XLGB Pill) through a non-intervention observational way.
- Trial name
- NCT03091556
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Beijing 302 Hospital